rebel Financial rebel Financial
← All Posts
ASMB

ASSEMBLY BIOSCIENCES, INC.

June 05, 2026 • Author: Phil Ratcliff • ASMB
Item Proposal Vote
1 Elect the nine nominees named in the attached proxy statement to our Board of Directors (the Board)
1.1 Anthony E. Altig ✓ For
1.2 Tomas Cihlar, Ph.D. ✗ Against
1.3 Gina Consylman ✓ For
1.4 Robert D. Cook II ✗ Against
1.5 Sir Michael Houghton, Ph.D. ✓ For
1.6 Lisa R. Johnson-Pratt, M.D. ✓ For
1.7 Susan Mahony, Ph.D. ✓ For
1.8 John G. McHutchison, A.O., M.D. ✓ For
1.9 Jason A. Okazaki ✗ Against
2 Approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice ✓ For
3 Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 ✓ For
4 Approve an amendment to the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,200,000 shares ✓ For
5 Approve an amendment to the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan to increase the number of shares reserved for issuance thereunder to 515,000 shares ✓ For
Attachments
📄
ASMB_PROXY_STATEMENT.pdf 1.7 MB
📄
ASMB_ANNUAL_REPORT_2025.pdf 7.1 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.